US EditionNouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
12 Articles
12 Articles
As detailed by the Spanish Association Against Cancer, colon cancer is the most frequent or highest incidence tumor in Spain. But, in addition, it is the third most globally diagnosed type. These data are those that encourage researchers to continue finding methods that can slow down and even prevent its development. One of them is Eduardo Vilar-Sánchez, Spanish who has led a last trial with promising results that arrives in vaccine format, call…
Investigator Eduardo Vilar-Sánchez has managed to stop the appearance of polyps in 45 patients with Lynch syndrome, a disease that predisposes them to colon cancer
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancersNOUS-209 is an off-the-shelf cancer immunotherapy designed to induce T cells against neoantigens present in tumors and precancer lesions in LS carriersPublication in Nature Medicine underscores significance of NOUS-209 clinical data and its innovative approach to intercept cancer before it developsData support advanci…
Preventive immunization Nous-209 works in a first trial with patients who are 17 times more at risk for tumours than the general population
The clinical trial achieved an immune response in people with Lynch syndrome, who are at increased risk of developing this type of tumor.
The clinical trial has focused on patients with Lynch syndrome, a group with a high risk of colorectal tumor, the most diagnosed in Spain.
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
